These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

326 related items for PubMed ID: 11275990

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Targeting bcl-2 gene to delay androgen-independent progression and enhance chemosensitivity in prostate cancer using antisense bcl-2 oligodeoxynucleotides.
    Gleave ME, Miayake H, Goldie J, Nelson C, Tolcher A.
    Urology; 1999 Dec; 54(6A Suppl):36-46. PubMed ID: 10606283
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of progression to androgen-independence by combined adjuvant treatment with antisense BCL-XL and antisense Bcl-2 oligonucleotides plus taxol after castration in the Shionogi tumor model.
    Miyake H, Monia BP, Gleave ME.
    Int J Cancer; 2000 Jun 15; 86(6):855-62. PubMed ID: 10842201
    [Abstract] [Full Text] [Related]

  • 5. Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides.
    Miayake H, Tolcher A, Gleave ME.
    J Natl Cancer Inst; 2000 Jan 05; 92(1):34-41. PubMed ID: 10620631
    [Abstract] [Full Text] [Related]

  • 6. Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models.
    Miyake H, Nelson C, Rennie PS, Gleave ME.
    Cancer Res; 2000 May 01; 60(9):2547-54. PubMed ID: 10811138
    [Abstract] [Full Text] [Related]

  • 7. Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo.
    Miyake H, Chi KN, Gleave ME.
    Clin Cancer Res; 2000 May 01; 6(5):1655-63. PubMed ID: 10815883
    [Abstract] [Full Text] [Related]

  • 8. Polymeric micellar paclitaxel phosphorylates Bcl-2 and induces apoptotic regression of androgen-independent LNCaP prostate tumors.
    Leung SY, Jackson J, Miyake H, Burt H, Gleave ME.
    Prostate; 2000 Jul 01; 44(2):156-63. PubMed ID: 10881025
    [Abstract] [Full Text] [Related]

  • 9. Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the antiapoptotic gene clusterin.
    Zellweger T, Miyake H, July LV, Akbari M, Kiyama S, Gleave ME.
    Neoplasia; 2001 Jul 01; 3(4):360-7. PubMed ID: 11571636
    [Abstract] [Full Text] [Related]

  • 10. Antisense Bcl-2 oligodeoxynucleotides inhibit progression to androgen-independence after castration in the Shionogi tumor model.
    Miyake H, Tolcher A, Gleave ME.
    Cancer Res; 1999 Aug 15; 59(16):4030-4. PubMed ID: 10463603
    [Abstract] [Full Text] [Related]

  • 11. Castration-induced up-regulation of insulin-like growth factor binding protein-5 potentiates insulin-like growth factor-I activity and accelerates progression to androgen independence in prostate cancer models.
    Miyake H, Pollak M, Gleave ME.
    Cancer Res; 2000 Jun 01; 60(11):3058-64. PubMed ID: 10850457
    [Abstract] [Full Text] [Related]

  • 12. GLI2 knockdown using an antisense oligonucleotide induces apoptosis and chemosensitizes cells to paclitaxel in androgen-independent prostate cancer.
    Narita S, So A, Ettinger S, Hayashi N, Muramaki M, Fazli L, Kim Y, Gleave ME.
    Clin Cancer Res; 2008 Sep 15; 14(18):5769-77. PubMed ID: 18794086
    [Abstract] [Full Text] [Related]

  • 13. Inhibition of LncaP prostate cancer cells by means of androgen receptor antisense oligonucleotides.
    Eder IE, Culig Z, Ramoner R, Thurnher M, Putz T, Nessler-Menardi C, Tiefenthaler M, Bartsch G, Klocker H.
    Cancer Gene Ther; 2000 Jul 15; 7(7):997-1007. PubMed ID: 10917202
    [Abstract] [Full Text] [Related]

  • 14. A novel antisense oligonucleotide inhibiting several antiapoptotic Bcl-2 family members induces apoptosis and enhances chemosensitivity in androgen-independent human prostate cancer PC3 cells.
    Yamanaka K, Rocchi P, Miyake H, Fazli L, Vessella B, Zangemeister-Wittke U, Gleave ME.
    Mol Cancer Ther; 2005 Nov 15; 4(11):1689-98. PubMed ID: 16275990
    [Abstract] [Full Text] [Related]

  • 15. Use of antisense oligonucleotides targeting the antiapoptotic gene, clusterin/testosterone-repressed prostate message 2, to enhance androgen sensitivity and chemosensitivity in prostate cancer.
    Gleave ME, Miyake H, Zellweger T, Chi K, July L, Nelson C, Rennie P.
    Urology; 2001 Aug 15; 58(2 Suppl 1):39-49. PubMed ID: 11502446
    [Abstract] [Full Text] [Related]

  • 16. Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer.
    Rocchi P, So A, Kojima S, Signaevsky M, Beraldi E, Fazli L, Hurtado-Coll A, Yamanaka K, Gleave M.
    Cancer Res; 2004 Sep 15; 64(18):6595-602. PubMed ID: 15374973
    [Abstract] [Full Text] [Related]

  • 17. Inhibition of LNCaP prostate tumor growth in vivo by an antisense oligonucleotide directed against the human androgen receptor.
    Eder IE, Hoffmann J, Rogatsch H, Schäfer G, Zopf D, Bartsch G, Klocker H.
    Cancer Gene Ther; 2002 Feb 15; 9(2):117-25. PubMed ID: 11857028
    [Abstract] [Full Text] [Related]

  • 18. Alpha-tomatine synergises with paclitaxel to enhance apoptosis of androgen-independent human prostate cancer PC-3 cells in vitro and in vivo.
    Lee ST, Wong PF, Hooper JD, Mustafa MR.
    Phytomedicine; 2013 Nov 15; 20(14):1297-305. PubMed ID: 23920276
    [Abstract] [Full Text] [Related]

  • 19. Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer.
    Thalmann GN, Sikes RA, Chang SM, Johnston DA, von Eschenbach AC, Chung LW.
    J Natl Cancer Inst; 1996 Jun 19; 88(12):794-801. PubMed ID: 8637045
    [Abstract] [Full Text] [Related]

  • 20. Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer.
    Eigl BJ, Eggener SE, Baybik J, Ettinger S, Chi KN, Nelson C, Wang Z, Gleave ME.
    Clin Cancer Res; 2005 Jul 01; 11(13):4905-11. PubMed ID: 16000589
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.